Shots:
- The P-II (ALPACA) trial assessed lepodisiran (16, 96, or 400mg) vs PBO for ~18mos. in 320 pts, who were dosed at baseline & day 180, with an additional arm receiving 400mg at baseline & PBO at day 180; P-III [ACCLAIM-Lp(a)] trial enrollment is ongoing
- Trial met its 1EP, with 400mg reducing Lp(a) by 93.9% over 60-180 days; 16 mg & 96 mg showed 40.8% & 75.2% reductions, respectively; impact of additional lepodisiran doses remain unknown
- 2EPs showed 400mg (dosed twice) reduced Lp(a) by 94.8% (day 30-360), sustained at 91% at ~1yr. & 74.2% at ~1.5yrs., with ApoB reductions of 14.1% (day 60) & 13.7% (day 180), maintained through day 540; data was presented at ACC 2025 & published in The NEJM
Ref: Eli Lilly | Image: Eli Lilly
Related News:- Eli Lilly Reveals VIVID-2 Study Data of Omvoh to Treat Crohn’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
